GlaxoSmithKline and Theravance (now Innoviva) developed the once-daily inhaled combination, Anoro, consisting of umeclidinium and vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Umeclidinium is a long-acting muscarinic antagonist, while vilanterol is a long-acting beta 2 agonist. In December 2013, the US Food and Drug Administration approved Anoro as a maintenance therapy for the treatment of airflow obstruction in patients with COPD. In May 2014, the therapy received marketing authorization in the EU and was later approved in Japan in July 2014.
LIST OF FIGURES
12 Figure 1: Anoro for COPD – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Anoro for COPD
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Anoro for COPD
17 Figure 4: Anoro sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Anoro drug profile
7 Table 2: Anoro Phase III data in COPD
18 Table 3: Anoro sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726